This page shows the latest Disarm Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Deal could eventually be worth up to $1.36bn. Eli Lilly is set to acquire private biotech company Disarm Therapeutics for an initial upfront payment of $135m, with a focus on ... Disarm’s focus is on the development of a new class of disease-modifying
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
No results were found
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...